Unless corrected, the Federal Circuit’s ruling in GSK v. Teva widely threatens the ability of generic and biosimilar developers to deliver more affordable medicines to patients in as timely a manner as possible.
Access! 2023 + IGBA 2023 Conference - Last chance to register, join us in Orlando, FL on Feb 13-16!